Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome

Blood

Volumn 90, Issue 6, 1997, Pages 2502-2508

  Salzberger, Bernd ^a   Bowden, Raleigh A ^a   Hackman, Robert C ^a   Davis, Chris ^a   Boeckh, Michael ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; CREATININE; FLUCONAZOLE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

EID: 0030821610     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.6.2502.2502_2502_2508     Document Type: Article

References (34)

1. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325:1601, 1991
2. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 324:1005, 1991
3. Goodrich JM, Bowden RA, Fisher L, Kelley C, Schoch G, Meyers JD: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173, 1993
4. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, Champlin RE: Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 118:179, 1993
5. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, Mackes P, Herter M, Klingebiel T, Löffler J, Wagner S, Müller CA: Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86:2815, 1995
6. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA: Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation - A randomized double-blind study. Blood 88:4063, 1996
7. Anonymous: Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Arch Intern Med 155:65, 1995
8. Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, Resta S, Dunn D, Gamberg P, Ratkovec RM, Richenbacher WE, Millar RC, DuMond C, De Amond B, Sullivan V, Cheney T, Buhles W, Stinson EB: A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 326:1182, 1992
9. Winston DJ, Wirin D, Shaked A, Busuttil RW: Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 346:69, 1995
10. Duncan SR, Grgurich WF, Iacono AT, Burckart GJ, Yousem SA, Paradis IL, Williams PA, Johnson BA, Griffith BP: A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 150:146, 1994
11. Sommadossi J-P, Carlisle R: Toxicity of 3′-azido-3′-deoxythymidine and 9-( 1,3-dihydroxy-2-propoxymethyl)guanine for normalhuman hematopoietic progenitor cells in vitro. Antimicrob Agent Chemother 31:452, 1987
12. Buckner CD, Clift RA, Appelbaum FR, Storb R, Petersen FB, Sanders JE, Thomas ED, Hansen JA: Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia. Bone Marrow Transplant 7:6, 1992 (suppl 2)
13. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, Martin P, McDonald, Sanders JE, Schoch G, Singer J, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR: Marrow transplantation for chronic myeloid leukemia: A randomized study comapring cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036, 1994
14. Lynch MH, Peterson FB, Appelbaum FR, Bensinger WI, Clift RA, Storb R, Sanders JE, Hansen JA, Buckner CD: Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. Bone Marrow Transplant 15:59, 1995
15. Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR, Chancey TR, Doney K, Flowers M, Martin P, Nash R, Schoch G, Sullivan KM, Witherspoon RP, Storb R: Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease - A prospective, randomized trial. Blood 89:3880, 1997
16. Storb R, Leisenring W, Deeg HJ, Anasetti C, Appelbaum F, Bensinger W, Buckner CD, Clift RA, Doney K, Hansen J, Martin P, Sanders J, Stewart P, Sullivan K, Thomas ED, Witherspoon R: Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. Blood 83:2749, 1994 (letter)
17. Przepiorka D, Weisdorf D, Martin P, Klingemann H-G, Beatty P, Hows J, Thomas ED: Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825, 1995
18. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM: Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 4:247, 1989
19. Hartsock RJ, Smith EB, Petty CS: Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest. Am J Clin Pathol 43:326, 1965
20. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31, 1976
21. Torok-Storb B, Fries B, Myerson D: Cytomegalovirus mediated cytopenias, in Guignon M (ed): The Negative Regulation of Hematopoiesis, vol 229. John Libbey Eurotext Ltd, 1993, p 383
22. Sayer HG, Longton G, Bowden R, Pepe M, Storb R: Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 84:1328, 1994
23. Bowden RA, Cays M, Gooley T, Mamelok R, van Burik J-A: Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 173:1208, 1996
24. Kalbfleisch JD, Prentice RL: The statistical analysis of failure time data. New York, NY, Wiley, 1980
25. Pepe MS, Longton GM, Pettinger M, Mori M, Fisher LD, Storb R: Summarizing data on survival, relapse and chronic graft-versus-host disease after bone marrow transplantation: Motivation for and description of new methods. Br J Haematol 83:602, 1993
26. SPSS I: SPSS 6.1.1. Chicago, SPSS Inc. 1995
27. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 Patients. Ann Intern Med 118:255, 1993
28. Fink JC, Cooper MA, Burkhart KM, McDonald GB, Zager RA: Marked enzymuria after bone marrow transplantation: A correlate of veno-occlusive disease induced "hepatorenal syndrome". J Am Soc Nephrol 6:1655, 1995
29. Fletcher C, Sawchuck R, Chinnock B, de Miranda P, Balfour HH: Human pharmakokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 40:281, 1986
30. Yuen GJ, Drusano GL, Fletcher C, Capparelli E, Connor JD, Lalezari JP, Drew L, Follansbee S, Busch D, Jacobson M, Spector SA, Squires K, Buhles W: Population Differences in Ganciclovir Clearance as Determined by Nonlinear Mixed Effects Modelling. Antimicrob Agents Chemother 39:2350, 1995
31. Shepp DH, Dandliker PS, de Miranda P, Burnette TC, Cederberg DM, Kirk LE, Meyers JD: Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 103:368, 1985
32. Atkinson K, Downs K, Golenia M, Biggs J, Marshall G, Dodds A, Concannon A: Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: Absence of clinical cytomegalovirus infection. Br J Haematol 79:57, 1991
33. Przepiorka D, Ippoliti C, Panini A, Goodrich J, Giralt S, van Besten K, Mehra R, Deisseroth AB, Andersson B, Luna M, Tarrand JJ, Champlin RE: Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplant. Bone Marrow Transplant 13:461, 1994
34. Atkinson K, Arthur C, Bradstock K, Dale B, Downs K, Gibson J, Golenia M, Ho J, Joshua D, Juttner C, Shaw P, Sheridan W, Szer J, Vowels M and the Australasian Bone Marrow Transplant Study Group: Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group. Bone Marrow Transplant 16:401, 1995